177 related articles for article (PubMed ID: 38205840)
1. Novel uses of complement inhibitors in myasthenia gravis-Two case reports.
Zadeh S; Price H; Drews R; Bouffard MA; Young LH; Narayanaswami P
Muscle Nerve; 2024 Mar; 69(3):368-372. PubMed ID: 38205840
[TBL] [Abstract][Full Text] [Related]
2. Real-world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis.
Tokuyasu D; Suzuki S; Uzawa A; Nagane Y; Masuda M; Konno S; Kubota T; Samukawa M; Sugimoto T; Ishizuchi K; Oyama M; Yasuda M; Akamine H; Onishi Y; Suzuki Y; Kawaguchi N; Minami N; Kimura T; Takahashi MP; Murai H; Utsugisawa K
Ann Clin Transl Neurol; 2024 May; 11(5):1338-1346. PubMed ID: 38572524
[TBL] [Abstract][Full Text] [Related]
3. Clinical Experience with Eculizumab in Treatment-Refractory Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis.
Katyal N; Narula N; Govindarajan R
J Neuromuscul Dis; 2021; 8(2):287-294. PubMed ID: 33325394
[TBL] [Abstract][Full Text] [Related]
4. Ravulizumab: A Review in Generalised Myasthenia Gravis.
Kang C
Drugs; 2023 Jun; 83(8):717-723. PubMed ID: 37166620
[TBL] [Abstract][Full Text] [Related]
5. Retrospective Analysis of Eculizumab in Patients with Acetylcholine Receptor Antibody-Negative Myasthenia Gravis: A Case Series.
Datta S; Singh S; Govindarajan R
J Neuromuscul Dis; 2020; 7(3):269-277. PubMed ID: 32444555
[TBL] [Abstract][Full Text] [Related]
6. Immune Checkpoint Inhibition-Related Myasthenia-Myositis-Myocarditis Responsive to Complement Blockade.
Nelke C; Pawlitzki M; Kerkhoff R; Schroeter CB; Aktas O; Neuen-Jacob E; Polzin A; Meuth SG; Ruck T
Neurol Neuroimmunol Neuroinflamm; 2024 Jan; 11(1):. PubMed ID: 37884388
[TBL] [Abstract][Full Text] [Related]
7. Eculizumab in Adolescent Patients With Refractory Generalized Myasthenia Gravis: A Phase 3, Open-Label, Multicenter Study.
Brandsema JF; Ginsberg M; Hoshino H; Mimaki M; Nagata S; Rao VK; Ruzhansky K; Suresh N; Tiongson E; Yamanouchi H; Frick G; Hicks E; Liao S; Howard JF;
Pediatr Neurol; 2024 Jul; 156():198-207. PubMed ID: 38810600
[TBL] [Abstract][Full Text] [Related]
8. The use of eculizumab in ventilator-dependent myasthenia gravis patients.
Usman U; Chrisman C; Houston D; Haws CC; Wang A; Muley S
Muscle Nerve; 2021 Aug; 64(2):212-215. PubMed ID: 34008175
[TBL] [Abstract][Full Text] [Related]
9. Eculizumab for myasthenic exacerbation during treatment with immune-checkpoint inhibitors.
Fionda L; Rossini E; Lauletta A; Leonardi L; Tufano L; Costanzo R; Marchetti P; Salvetti M; Garibaldi M; Morino S; Antonini G
Neurol Sci; 2024 Mar; 45(3):1243-1247. PubMed ID: 38108913
[TBL] [Abstract][Full Text] [Related]
10. Starting eculizumab as rescue therapy in refractory myasthenic crisis.
Vinciguerra C; Bevilacqua L; Toriello A; Iovino A; Piscosquito G; Calicchio G; Barone P
Neurol Sci; 2023 Oct; 44(10):3707-3709. PubMed ID: 37306795
[TBL] [Abstract][Full Text] [Related]
11. Eculizumab treatment for myasthenia gravis subgroups: 2021 update.
Jiao L; Li H; Guo S
J Neuroimmunol; 2022 Jan; 362():577767. PubMed ID: 34823117
[TBL] [Abstract][Full Text] [Related]
12. [Eculizumab Treatment for Refractory Generalized Myasthenia Gravis].
Uzawa A; Kuwabara S
Brain Nerve; 2019 Jun; 71(6):565-570. PubMed ID: 31171753
[TBL] [Abstract][Full Text] [Related]
13. Improved outcomes with early immunosuppression in patients with immune-checkpoint inhibitor induced myasthenia gravis, myocarditis and myositis: a case series.
Weaver JM; Dodd K; Knight T; Chaudhri M; Khera R; Lilleker JB; Roberts M; Lorigan P; Cooksley T
Support Care Cancer; 2023 Aug; 31(9):518. PubMed ID: 37572133
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibitor-Induced Myositis/Myocarditis with Myasthenia Gravis-like Misleading Presentation: A Case Series in Intensive Care Unit.
Deharo F; Carvelli J; Cautela J; Garcia M; Sarles C; Maues de Paula A; Bourenne J; Gainnier M; Bichon A
J Clin Med; 2022 Sep; 11(19):. PubMed ID: 36233479
[TBL] [Abstract][Full Text] [Related]
15. Clinical Efficacy and Safety of Eculizumab for Treating Myasthenia Gravis.
Xiao H; Wu K; Liang X; Li R; Lai KP
Front Immunol; 2021; 12():715036. PubMed ID: 34456922
[TBL] [Abstract][Full Text] [Related]
16. Development of generalized disease at 2 years in patients with ocular myasthenia gravis.
Kupersmith MJ; Latkany R; Homel P
Arch Neurol; 2003 Feb; 60(2):243-8. PubMed ID: 12580710
[TBL] [Abstract][Full Text] [Related]
17. Successful Transition from Plasma Exchange to Eculizumab in Acetylcholine Receptor Antibody- and Muscle-Specific Kinase (MuSK) Antibody-Negative Myasthenia Gravis: A Case Report.
Greenwood GT; Lynch Z
Am J Case Rep; 2020 May; 21():e921431. PubMed ID: 32417849
[TBL] [Abstract][Full Text] [Related]
18. Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension.
Mantegazza R; Wolfe GI; Muppidi S; Wiendl H; Fujita KP; O'Brien FL; Booth HDE; Howard JF;
Neurology; 2021 Jan; 96(4):e610-e618. PubMed ID: 33229455
[TBL] [Abstract][Full Text] [Related]
19. Severe worsening of myasthenic symptoms after the eculizumab discontinuation.
Uzawa A; Ozawa Y; Yasuda M; Kuwabara S
J Neuroimmunol; 2020 Dec; 349():577424. PubMed ID: 33068973
[TBL] [Abstract][Full Text] [Related]
20. Pembrolizumab-induced myasthenia gravis: A fatal case report.
March KL; Samarin MJ; Sodhi A; Owens RE
J Oncol Pharm Pract; 2018 Mar; 24(2):146-149. PubMed ID: 28147928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
